Developing antibodies to fight bacterial infections
Official title: Antibody Core
Funded at Scripps Research Institute, the · NIH-11082426 · Data updated 2026-11-12
This study is all about making special proteins called antibodies that can help your body fight off bacterial infections, and it aims to create new treatments that could boost your immune system if you're dealing with these kinds of illnesses.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | May 9, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $194,587 |
| NIH project number | 5P01AI172525-03 |
| Project ID | NIH-11082426 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from bacterial infections or those at high risk of such infections.
✕Less likely to help
Patients with viral infections or non-infectious diseases may not receive any benefit from this research.
What this research studies
This research focuses on the engineering and production of antibodies that can target and neutralize bacterial infections. It involves creating both polyclonal and monoclonal antibodies through various methods, including immunization of animals and advanced techniques like single B cell antibody chain sequencing. The antibodies produced will be characterized for their effectiveness in binding to specific bacterial antigens, which is crucial for developing new treatments. Patients may benefit from the resulting therapies that could enhance their immune response against bacterial diseases.
Why it matters
Potential benefit: If successful, this research could lead to new antibody-based therapies that improve treatment outcomes for patients with bacterial infections.
How similar studies have gone: Previous research has shown success in developing antibody therapies for bacterial infections, indicating that this approach has potential for meaningful advancements.
Where this research is happening
-
Scripps Research Institute, the
La Jolla, United States Active
Researchers
- Principal investigator: Teyton, Luc — Scripps Research Institute, the
- Study coordinator: Teyton, Luc
Related research
Other NIH-funded projects on the same topics.
-
The Participant Center helps people join and stay in a nationwide health study
A nationwide program to support people in joining, contributing biosamples, and staying connected to a large health study in the United States.
-
Data Sharing and Bioinformatics Core for Viral Systems Biology
A center-led effort to manage, share, and interpret large viral systems biology data using open tools and a community-friendly portal.
-
Germline-targeted HIV vaccines using membrane liposome tech to trigger bnAbs
A new HIV vaccine approach aims to spark broadly neutralizing antibodies by showing MPER on membranes, tested in models and early studies to guide future human trials.
-
Antivirals for hemorrhagic fever viruses like LASV, SFTSV, and EBOV
A multi-institutional effort to find and validate antiviral compounds that block key viral proteins from LASV, SFTSV, and EBOV to help people at risk from serious hemorrhagic fevers.
-
Developing new antivirals for flaviviruses
A research team is working to create oral antiviral drugs targeting flaviviruses to treat infections that affect millions of people.
-
CoV inhibitors targeting non-enzymatic SARS-CoV-2 components
A multicenter research effort seeks antiviral ideas that block SARS-CoV-2 parts that don’t work through traditional enzymes, aiming to help people affected by COVID-19.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.